-
, drug discovery and development for rare diseases. Our innovative and ambitious joint-PhD program will train highly qualified young scientists in new scientific and technological knowledge. At the end
-
, cancer metastasis, and additional immune-related diseases. Currently only maraviroc has been approved as an extracellular CCR5 blocker, but this drug suffers from drawbacks, most notoriously hepatotoxicity
Searches related to drug delivery
Enter an email to receive alerts for drug-delivery positions